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ABSTRACT
Objective To compare the effectiveness of oral quinine
with that of artemether-lumefantrine in treating
uncomplicated malaria in children.
Design Randomised, open label effectiveness study.
Setting Outpatient clinic of Uganda’s national referral
hospital in Kampala.
Participants 175 children aged 6 to 59 months with
uncomplicated malaria.
Interventions Participants were randomised to receive
oral quinine or artemether-lumefantrine administered by
care givers at home.
Main outcome measures Primary outcomes were
parasitological cure rates after 28 days of follow-up
unadjusted and adjusted by genotyping to distinguish
recrudescence from new infections. Secondary outcomes
were adherence to study drug, presence of gametocytes,
recovery of haemoglobin concentration from baseline at
day 28, and safety profiles.
Results Using survival analysis the cure rate unadjusted
by genotyping was 96% for the artemether-lumefantrine
group compared with 64% for the quinine group (hazard
ratio10.7,95%confidenceinterval3.3to35.5,P=0.001).
In the quinine group 69% (18/26) of parasitological
failureswereduetorecrudescencecomparedwithnonein
the artemether-lumefantrine group. The mean adherence
to artemether-lumefantrine was 94.5% compared with
85.4% to quinine (P=0.0008). Having adherence levels of
80% or more was associated with a decreased risk of
treatment failure (0.44, 0.19 to 1.02, P=0.06). Adverse
events did not differ between the two groups.
Conclusions The effectiveness of a seven day course of
quinine for the treatment of uncomplicated malaria in
Ugandan children was significantly lower than that of
artemether-lumefantrine. These findings question the
advisability of the recommendation for quinine therapy
for uncomplicated malaria in Africa.
Trial registration ClinicalTrials.gov NCT00540202.
INTRODUCTION
Most episodes of falciparum malaria are uncompli-
cated and treated with short courses of oral
antimalarials. Chloroquine was the mainstay of ther-
apy for uncomplicated falciparum malaria until the
late 1990s. As a result of the increasing resistance to
chloroquine, sulfadoxine-pyrimethamine or amodia-
quinewasadoptedasfirstlinetherapyinseveralcoun-
tries. However, increasing resistance to both of these
drugs has led to recommendations for combination
therapy, preferably those based on artemisinin.
1 Con-
sequentlyartemether-lumefantrineorartesunate-amo-
diaquine have been adopted as first line regimens for
uncomplicated falciparum malaria in nearly all coun-
tries in Africa.
Quinine was the first established antimalarial, and it
has been used to treat malaria for centuries.
2 Intra-
venousquinineisthe standardtherapyforseverefalci-
parum malaria in all African countries. Many malaria
endemic countries that recently adopted artemisinin
based combination therapies as first line therapy
recommend quinine as the second line regimen for
uncomplicated malaria despite guidelines from the
World Health Organization that antimalarial medi-
cines should be used in combination.
3 Probably such
a choice was influenced by the few alternatives to qui-
nine at the time of the policy change to artemisinin
based combination therapy. Of the 41 African coun-
tries thathave adoptedartemisininbasedcombination
therapies as the first line treatment for uncomplicated
malaria, 29 currently recommend quinine as second
line therapy.
4 In addition, as a result of the decreased
efficacy of older agents and limited availability of arte-
misinin based combination therapies, quinine is
increasingly used as a first line drug in the treatment
of uncomplicated malaria in Africa. A survey in
Uganda in 2007 reported that in rural health facilities
quinine was prescribed for only 4% of patients with
uncomplicatedmalaria
5whereasattheoutpatientfacil-
ity of Mulago Hospital, Kampala, this proportion was
as high as 26% (unpublished data). Thus, although it is
not listed asa first line drugfor uncomplicated malaria
in any country, quinine is still widely used for this pur-
pose.
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treatment policy recommends quinine, given in its
tablet formulation, as the second line treatment for
uncomplicated malaria. This recommendation is
based on the longstanding assumption that the medi-
cine is efficacious, given the lack of historical and con-
temporary evidence to the contrary. Although there
are anecdotal reports that its effectiveness is compro-
mised by poor adherence to treatment, noreliable evi-
dence shows this. Indeed it was for these reasons that
we carried out this study.
Despite increasing use of quinine, few studies of its
efficacy in the management of uncomplicated malaria
havebeenpublishedrecently.Inparticular,fewstudies
haveusedmodernmethodstodetermineoutcomes(at
least28daysoffollow-upandmoleculargenotypingto
distinguish recrudescence from new infections after
treatment). Treatment of uncomplicated malaria with
a shorter course (<7 days) of quinine was generally
inferiortoatreatmentcourseofsevendays.
6Consider-
ing seven day courses, available recent studies have
shown failure rates with quinine for uncomplicated
malaria of over 10% at 28 days in Sudan
7 and
Thailand.
8 Quinine efficacy may be particularly poor
in pregnant women; both genotype adjusted efficacy
after supervised seven day therapy in Thailand
9 and
unadjusted effectiveness after seven day therapy in
Gabon
10wereonlyabout60%.However,otherstudies
have shown excellent efficacy for quinine, including
over 95% success after 28 days for the treatment of fal-
ciparum malaria in Equatorial Guinea,
11 Venezuela,
12
and returned travellers in France.
13
As study designs have varied, it is difficult to ascer-
tain if limitations in quinine effectiveness in some stu-
diesweredueprincipallytotruedrugresistance,varied
pharmacokinetics, poor compliance with a seven day
regimen, or a combination of these factors. However,
availableevidencesuggeststhatAfricanstrainsofPlas-
modium falciparum generally remain sensitive to
quinine
14-19andthatvariabilityinquininepharmacoki-
netics does not explain varied treatment responses.
20
Thus poor compliance with a seven day quinine regi-
men might contribute importantly to limitations in the
drug’s efficacy. Poor compliance with quinine, com-
pared with shorter regimens, has been documented.
21
Inadequate compliance is probably due both to the
need for frequent dosing over one week and to
known poor tolerance of quinine, which often causes
the syndrome of cinchonism, including nausea, head-
ache, tinnitus, and blurred vision
22 at treatment doses.
Consideringtheuncertaineffectivenessofquinineand
its increasing role in the treatment of uncomplicated
malaria in Africa, we compared its effectiveness with
thatofartemether-lumefantrine,thenewfirstlinether-
apy for uncomplicated malaria in Uganda.
METHODS
Thiswasanopenlabelrandomisedeffectivenessstudy
to compare parasitological and clinical cure rates and
adherence between quinine and artemether-lumefan-
trine in children with uncomplicated malaria.
Participants were recruited from the main outpatient
clinic at Uganda’s national referral hospital, Mulago,
in Kampala.
Children aged 6 to 59 months were included if they
had an axillary temperature of 37.5°C or more or a
history of fever in the past 24 hours, microscopically
confirmed P falciparum mono-infection with any den-
sityofasexualparasites,abilitytotolerateoraltherapy,
and no history of antimalarial drug intake in the pre-
ceding two weeks. Children were not recruited if they
met at least one of several exclusion criteria: a history
of allergy to quinine or artemether-lumefantrine, evi-
dence of severe malaria or other concomitant febrile
illness, or residence more than 20 km from the health
clinic. Severe malaria was defined according to WHO
criteria.
23
Enrolment procedures
Participants with suspected malaria during an outpati-
ent visit (day 0) were assessed for eligibility and
referredtothelaboratorytoobtainthick(parasiteden-
sity) and thin (parasite species) blood smears. Partici-
pants fulfilling all selection criteria had a standard
baseline history and physical examination done by a
studydoctor.Studydata wererecordedoncaserecord
forms. Participants were identified by their initials and
study identification numbers. Haemoglobin was mea-
suredfromfingerprickbloodsamplesusingaportable
spectrophotometer (HemoCue; Angelhom, Sweden).
Blood samples were also stored on Whatmann filter
paper for subsequent molecular studies.
Randomisation and treatment
Participants were randomly assigned to receive oral
quinineorartemether-lumefantrine.Blockrandomisa-
tion was used with blocks of 20. Computer generated
randomisation codes were prepared by an indepen-
dentindividualandenclosedinsequentiallynumbered
opaque sealed envelopes, each of which contained the
treatment allocation. The envelopes were assigned in
sequential order to participants after inclusion. Partici-
pantsinthequininearmreceivedasevendaycourseof
quinine sulphate as 10 mg/kg body weight per dose
three times daily. Quinine sulphate was provided as
300 mg tablets (Rene Pharmaceutical, Kampala,
Uganda); the quality of the drug was certified by the
Uganda National Drug Authority. The tablets were
divided when necessary to adjust the dosage for body
weight. Care givers were instructed by the study nurse
that the tablets should be taken with clean water every
eight hours. Participants in the artemether-lumefan-
trine arm received WHO recommended weight speci-
fic artemether-lumefantrine blister packs (Coartem;
Novartis Pharma, Basel, Switzerland): one tablet per
dose for body weight 10.0-14.9 kg, two tablets for
15.0-24.9 kg, three tablets for 25.0-34.9 kg, and four
tables for ≥35 kg. Care givers were instructed by the
study nurse to administer a dose of artemether-lume-
fantrine eight hours after the first dose and then each
morning and evening for the following two days, with
all doses given 30 minutes to one hour after food,
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study drugs was given under the supervision of the
study nurse, who then provided the remaining doses
to be taken at home. Participants were observed for
30 minutes; those who vomited received a repeat
dose. Care givers were informed that if any dose was
vomited up within 30 minutes of being given then
another should be administered, with the option of
coming to the clinic to collect replacement doses.
Care givers were counselled about the necessity of
complying withthe full treatmentcourse and potential
side effects of the drug. They were also encouraged to
bring their child to the study clinic if symptoms per-
sisted or reappeared. Concomitant drugs were pre-
scribed as needed and documented on case record
forms;antibioticswith antimalarial activity such astet-
racyclines,macrolides,andantifolateswerenotusedin
this study. At the end of the enrolment visit (day 0) the
participants were taken home by study staff. Care
givers were not aware that they would be visited at
home or assessed for adherence.
Follow-up
Afieldworkerandanursevisitedparticipantsathome,
on day 3 for the artemether-lumefantrine group and
day 7 for the quinine group, in both cases the day
after treatment was scheduled to be completed. At
this visit a questionnaire was used to assess adherence.
Informationcollectedincludedbasicpersonaldataand
the time each dose was given and the method used.
Whenpossibletheblisterpackofartemether-lumefan-
trine and the envelope for the quinine tablets were
examined for remaining tablets. At the end of this
visit participants in the artemether-lumefantrine arm
were given appointments for follow-up visits and par-
ticipants in the quinine group were taken to the clinic.
Thechildrenwerefollowedupfor28days,withfollow-
up visits scheduled for days 7, 14, and 28 for both
groups. Participants were also seen at the clinic on
any unscheduled day if they were unwell. On each of
these clinic visits a standardised history and physical
examination were done and blood smears obtained
by finger prick to determine the density of asexual
parasites, presence of gametocytes, and haemoglobin
concentration. Blood was also collected on filter paper
for subsequent molecular studies. In the event of treat-
ment failure, thin smearswere examined for species of
malaria parasite. Participants who failed treatment
weregivendihydroartemisininpluspiperaquinephos-
phate (Duo-cotexcin; Beijing Holley-Cotec, Beijing,
China) once daily for three days. Participants who
developed severe malaria were referred for treatment
with intravenous quinine. Those who for any reason
could not continue with the prescribed drugs, devel-
oped a serious concomitant illness that interfered
with outcome classification, could not be located
within 48 hours of a scheduled visit, or had consent
withdrawn were included in the analysis and censored
on their last day of follow-up.
Adverse events, defined as any unfavourable or
undesirable medical occurrence, were assessed at
each visit and recorded on case record forms. Associa-
tion of adverse events with the study drugs was classi-
fied as definite, probable, possible, unlikely, or none;
according to WHO and the guidelines of the Inter-
national Conference on Harmonisation.
24 Adverse
events were graded as serious if they were fatal or life
threatening, resulted in prolonged hospital stay,
caused persistent disability or incapacity, or required
medical or surgical interventions to prevent serious
outcomes.
Definition of adherence
Adherence to treatment was assessed by care givers’
report, and pill counts; overall adherence was the per-
centage of prescribed pills taken. For the artemether-
lumefantrine arm additional components to assess
adherence included an empty blister pack, a pill
count on the basis of tablets remaining in the blister
pack, care givers’ reported dosing schedule, and care
givers’reportonwhethertabletsweregivenafterfood.
On the basis of these factors, adherence to artemether-
lumefantrine was further qualified as optimal adher-
ence (all four components present), good adherence
(any three components present), or non-adherence
(two or fewer components present).
Laboratory procedures
The density of asexual malaria parasites was deter-
mined from thick blood smears stained with 2%
Giemsa for 30 minutes and a count of the number of
parasites per 200 white blood cells. Results were
expressed as number of parasites per microlitre,
assumingatotalwhitecellcountof8000permicrolitre.
Whennoasexualformswerefoundonexaminationof
100 high power fields, a negative result was recorded.
All slides were read by a second microscopist, and a
Participants screened (n=325)
Participants randomised (n=178)
Oral quinine (n=88) Artemether-lumefantrine (n=90)
Enrolled (n=86) Enrolled (n=89)
Excluded after randomisation for
vomiting more than three times (n=1)
Excluded during initial screening (n=147):
  Used antimalarials in past two weeks (n=74)
  Caregiver unwilling to provide informed consent (n=40)
  Residence >20 km from study clinic (n=19)
  Evidence of severe malaria or danger signs (n=11) 
  Concomitant febrile illness (n=3)
Excluded after randomisation for
vomiting more than three times (n=2)
Completed study (n=73) Completed study (n=74)
Excluded after enrolment (n=15):
  Lost to follow-up (n=14)
  Used other antimalarial (n=1)
Excluded after enrolment (n=13):
  Lost to follow-up (n=12)
  Used other antimalarial (n=1)
Fig 1 | Trial profile
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were blinded to treatment assignments.
For participants with recurrent parasitaemia after
day 3, we extracted DNA using chelex from filter
paper blood samples collected at enrolment and on
the day of failure.
25 To distinguish between recrudes-
cence and new infection, samples from enrolment and
the day of treatment failure were compared in a step-
wise manner on the basis of polymorphisms in mero-
zoite surface protein-1, merozoite surface protein-2,
and four microsatellite markers (TA40, TA60, TA81,
and PfPK2).
26
Outcome classification
Treatment outcomes were assessed according to
WHO guidelines as adequate clinical and para-
sitological response, early treatment failure, late clini-
calfailure,orlateparasitologicalfailure.
27Theprimary
effectivenessendpointwasthepolymerasechainreac-
tion adjusted clinical and parasitological cure rate at
day 28; secondary effectiveness outcomes were poly-
merase chain reaction unadjusted cure rate at day 28,
adherence to treatmentregimens, presenceof gameto-
cytes, recovery of haemoglobin concentration from
baseline at day 28, and incidence of adverse events.
Sample size estimation
This study was designed to test the hypothesis that the
effectiveness of quinine and artemether-lumefantrine
would not differ in the treatment of uncomplicated
malaria. We calculated that 151 patients would be
needed in each treatment arm using a 5% level of sig-
nificanceand90%power,andassumingadifferencein
adherence between the two groups of 19%
2128 and a
10% loss to follow-up.
Statistical analysis
Data were double entered into EPI-info software ver-
sion 6.04 and analysed using Stata version 10.0. Effec-
tiveness analysis was done using a modified intention
to treat with survival analysis. Categorical data were
compared by χ
2 test or Fisher’s exact test. Differences
between group means were analysed using Student’s t
test, applying log transformation when appropriate.
Risks of treatment failure were estimated using
Kaplan-Meier survival analysis. Two tailed P values
were used and all analyses were done at a 5% signifi-
cance level.
RESULTS
BetweenSeptember2007andApril2008atotalof325
children were screened for eligibility; of these, 147
(46%) were excluded, most commonly for use of anti-
malarialsinthetwoweeksbeforeenrolmentorunwill-
ingnessofthe primarycare giverstoprovideinformed
consent (fig 1). A planned interim analysis was under-
takenbythedataandsafetymonitoringboardafter178
participants had been recruited. The oral quinine
group met the predefined stopping rule of a significant
difference in cure rate using the O’Brien Fleming
method, with P<0.001, and the study was halted.
Eighty nine participants were enrolled to receive
artemether-lumefantrine and 86 to receive quinine.
During follow-up, 28 of the 175 participants (16%)
were excluded, 13 in the quinine arm (12 lost to fol-
low-up and one took other antimalarial) and 15 in the
artemether-lumefantrine arm (14 lost to follow-up and
one took other antimalarial). These participants were
included in the analysis and censored on their last day
of follow-up. Thus primary outcomes (unadjusted and
adjusted by genotyping) were available for 85% (73/
86) of participants in the quinine arm and 83% (74/
89)intheartemether-lumefantrinearm.Baselinechar-
acteristics were comparable between the groups
(table 1).
Primary treatment outcomes
Cure rates were significantly higher in the artemether-
lumefantrine group than in the quinine group. Using
survival analysis, cure rates unadjusted by genotyping
were 96% for the artemether-lumefantrine group and
64% for the quinine group (P<0.001; table 2). Early
treatment failure was uncommon; only two cases
were seen, both in the quinine arm (one child had
more than two convulsions in 24 hours and the other
hadprofusevomitingandprostration).Theywereboth
admitted to hospital and treated with intravenous qui-
nine. Participants were 10 times more likely to fail
treatment with oral quinine than with artemether-
lumefantrine (hazard ratio 10.7, 95% confidence inter-
val 3.3 to 35.5, P=0.001). The risk of treatment failure
unadjusted by genotyping was significantly higher in
the quininegroup thanin the artemether-lumefantrine
group(35.3%,95%confidenceinterval25.6%to47.4%
v4.1%,1.3%to12.0%):riskdifference31.3%(19.4%to
31.1%, P<0.001; table 3, fig 2). Genotyping showed
that 62% (16/26) of treatment failures in the quinine
groupwereduetorecrudescenceandthatalltreatment
failuresintheartemether-lumefantrinegroupweredue
tonewinfections.Whenonlytreatmentfailurescaused
by recrudescent parasites were considered, the risk of
failure with quinine was 23.1% (95% confidence inter-
val 14.9% to 35.0%) and with artemether-lumefantrine
was0(riskdifference23.1%,13.2%to33.1%,P<0.001;
table 3). Thepredictorsof treatmentfailureusing Cox
regression analysis included treatment with oral
Table 1 |Baseline characteristics of children with uncomplicated malaria randomised to
receive quinine or artemether-lumefantrine. Values are means (standard deviations) unless
stated otherwise
Characteristic
Quinine group
(n=86)
Artemether-lumefantrine group
(n=89)
Age (years) 2.0 (1.5) 2.1 (1.4)
No (%) girls 45 (52) 49 (55)
Weight (kg) 11.3 (3.3) 11.3 (3.0)
Axillary temperature (°C) 37.8 (1.4) 37.7 (1.3)
Haemoglobin concentration (g/l) 97 (20) 96 (21)
No (%) with gametocytes present 7 (8) 10 (11)
Parasite density (geometric mean/μl) 14 107 16 124
No (%) with parasitaemia <5000/μl 24 (28) 22 (25)
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3.34 to 36.57, P<0.001) and a temperature greater
than 37.5°C on day 0 (2.57, 1.17 to 5.66, P=0.02).
Secondary outcomes
Certain early responses to treatment, including clear-
anceoffeverandparasites,couldnotbeassessedinthis
study because participants were only seen at the study
clinic on days 0 and 7. Haemoglobin concentrations
improved equally in both groups during 28 days of
follow-up. Gametocytaemia was more common in
the quinine group at day 7 compared with the arte-
mether-lumefantrine group (14% (10/73) v 1% (1/74);
P=0.001).Byday28thegroupsdidnotdiffer(table 4).
Total person time with gametocytes was 20 weeks for
quinine compared with five weeks for artemether-
lumefantrine (P<0.01).
Reported adverse events did not differ between the
groups. Common side effects of quinine such as nau-
sea, headache, tinnitus, and blurred vision were not
noted. Severe adverse events occurred in only three
participants, two in the quinine group (one participant
had repeated seizures and the other had recurrent
vomiting and prostration). They were both classified
as early treatment failures. The third participant, in
the artemether-lumefantrine group, had repeated
vomiting on day 7 and a negative malaria smear result
at that time. This participant had a urinary tract infec-
tion and improved with antibiotic therapy.
Adherence
Adherence was assessed in 91% (160/175) of partici-
pants; 75 in the quinine group and 85 in the arte-
mether-lumefantrine group. This was done
successfully at the first home visit in 86% (n=138) of
the participants and on a second home visit in 12%
(n=19). Respondents were predominantly mothers
(94%, n=150) who were unemployed and stayed at
home (60%, n=96); 56% (n=89) were taking care of at
least two children and 35% (n=56) were taking care of
threeorfourchildren.Ninetypercent(n=144)ofthese
care givers had at least a primary school education.
Mean adherence in the artemether-lumefantrine
group was 95% (range 33-100%) and in the quinine
group was 85% (range 14-100%; P=0.0008). Overall,
non-adherence to treatment was higher in the quinine
groupthanintheartemether-lumefantrinegroup(55%
(41/75) v 17% (14/85); P=0.001). On the third day of
treatment the proportion of patients not adhering to
treatment was similar between the groups; 12% in the
artemether-lumefantrine arm and 13% in the quinine
arm (P=0.84). The proportion of participants who did
not adhere to quinine therapy, however, increased to
19%onthefifthdayoftreatment,31%onthesixthday,
and 44% on the seventh day. Only 34% (n=29) of par-
ticipants in the artemether-lumefantrine group had
optimal adherence whereas 51% (n=43) reported
good adherence. For both groups several reasons
were given for non-adherence. These included the
care givers forgetting to administer the drugs (50%,
23/46), the drugs being vomited up (22%, 10/46), the
child feeling better (7%, 3/46), the child unable to take
the drugs because of illness (4%, 2/46), and the care
giver not understanding dosage instructions (4%,
2/46). Difficulty in taking the prescribed drug was
reported for 32% (n=23) of participants in the quinine
group compared with 19% (n=14) in the artemether-
lumefantrine group (P=0.03). Participants in the qui-
nine group who were reported as having difficulty in
taking the drugs were less likely to adhere to the study
Unadjusted by genotyping
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Fig 2 | Kaplan-Meier curves for risk of treatment failure with
oral quinine and artemether-lumefantrine in Ugandan children
with uncomplicated malaria
Table 2 |Treatment outcomes of children aged 6 to 59 months with uncomplicated malaria
after 28 days of follow-up. Values are percentages (numbers)
Treatment outcomes Quinine group (n=86) Artemether-lumefantrine group (n=89)
Cure rate*† 64 (47) 97 (71)
Early treatment failure† 3( 2 ) 0
Late clinical failure†:
Due to recrudescence 12 (10) 0
Due to new infection 2 (5) 2 (2)
Genotyping unsuccessful 0 0
Total 21 (15) 3 (2)
Late parasitological failure†:
Due to recrudescence 2 (6) 0
Due to new infection 2 (2) 1 (1)
Genotyping unsuccessful 1 (1) 0
Total 7 (9) 1 (1)
No treatment outcome:
Lost to follow-up 14 (12) 16 (14)
Use of other antimalarials 1 (1) 1 (1)
Total 15 (13) 17 (15)
*Adequate clinical and parasitological response.
†Concerns 73 children in quinine arm and 74 in artemether-lumefantrine arm in whom treatment outcome was
assessed.
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difficulty; 39% (9/23) of participants who were
reported as having difficulty in taking the drugs were
non-adherent compared with only 21% (13/63) of
those who were not reported as having any difficulty
(P=0.08). This trend was not observed in the arte-
mether-lumefantrine group; 7% (1/14) of participants
who were reported as having difficulty in taking the
drugs were non-adherent compared with 9% (7/75)
who were not reported as having any difficulty
(P=0.79). In a multivariate analysis, predictors of non-
adherence included treatment with oral quinine
(P<0.001), being male (P<0.05), and vomiting
(P=0.02). Having a mean adherence of 80% or more
was associated with a decreased risk of treatment fail-
ure,althoughthiswasnotsignificant(hazardratio0.44,
95% confidence interval 0.19 to 1.02, P=0.06).
DISCUSSION
We compared the effectiveness of oral quinine with
artemether-lumefantrineinthetreatmentofuncompli-
cated malaria in Ugandan children aged 6 to
59 months. To our knowledge this was the first rando-
mised comparison of the effectiveness of these two
antimalarial drugs; artemether-lumefantrine was
highly effective, with only three late treatment failures
(all new infections) among 74 evaluable participants
(96% efficacy) after 28 days of follow-up. In contrast,
quinine was ineffective for treating uncomplicated
malaria, with failure in 26 of 73 evaluable participants
(64% efficacy), including two early treatment failures
and 16 late recrudescences. Participants treated with
quinine were 10 times more likely to fail therapy than
those treated with artemether-lumefantrine. These
results have striking implications. Quinine is the most
common second line therapy and is also increasingly
used as first line therapy for uncomplicated malaria in
Africa.Ourresultssuggestthatquinineisapoorchoice
forthetreatmentofuncomplicatedmalariaandthatits
use as first line or second line therapy for uncompli-
cated malaria needs to be reviewed.
Previous results for the efficacy and effectiveness of
oral quinine in uncomplicated malaria have been
mixed. Many studies have shown good efficacy with
quinine treatment for seven days,
11-13 but some have
shown efficacy
8 or effectiveness
7 below 90%, with par-
ticularly poor outcomes in studies of pregnant
women.
910 Several factors may have contributed to
the poor effectiveness of quinine in our study. Firstly,
althoughthequininehadbeencertifiedbytheUganda
National Drug Authority as being of good quality, we
did not verify this with specific tests, so that poor drug
quality cannot be ruled out. Secondly, resistance to
quinine may have led to treatment failures. Dimin-
ished sensitivity of cultured P falciparum has been
shown in Asia
2930 and South America,
31 but it seems
to be uncommon in parasites from Africa.
14-19 Thirdly,
variedpharmacokineticsmayhaveledtodruglevelsin
some participants that were inadequate to clear para-
sites after seven days of treatment. However, there is
little evidence for large variations in quinine
pharmacokinetics.
20 The fourth and probably most
likelyexplanationforthepooreffectivenessofquinine
in our study was poor compliance with the dosage
(three times daily for seven days). Quinine is well
known for poor tolerability owing to nausea, head-
ache, tinnitus, blurred vision, and other symptoms
thatincreaseoverafewdaysoftherapy,andpoorcom-
pliance with the drug has been documented.
21 In addi-
tion, even without problems of tolerability patients
may stop treatment early if symptoms of malaria
have resolved. Shortening the course of quinine has
been proposed as a strategy to improve adherence;
however, shorter courses have generally shown
decreased efficacy when compared with a seven day
regimen.
632 In our study, multiple reasons for non-
adherence were documented and poor adherence
with dosing guidelines was associated with treatment
failures. However, associations between adherence
andoutcomeswere modestand notstatisticallysignifi-
cant and did not fully explain the poor effectiveness of
quinine. Serum levels of quinine were not measured,
andsoadherencemeasuresdependedonprimarycare
givers’ reports and pill counts, which may have been
inaccurate. It remains unclear if our inability to fully
explain the poor effectiveness of quinine resulted
from limitations in our assessment of compliance or
was due to other factors.
In contrast with the results for quinine, the effective-
nessofartemether-lumefantrine,thenewfirstlinedrug
for uncomplicated malaria in Uganda, was excellent.
Thisresultisconsistentwiththosefromothereffective-
nessstudies,showingthatunsupervisedtreatmentwith
artemether-lumefantrine had the same efficacy (98%)
as supervised therapy for the treatment of uncompli-
cated malaria in Uganda
33 and that artemether-lume-
fantrine had excellent effectiveness in a region of
Tanzania with high rates of treatment failure with
Table 3 |Comparative effectiveness of oral quinine and artemether-lumefantrine treatment at day 28 in Ugandan children
with uncomplicated malaria
Outcome
Risk of failure (95% CI)
Risk difference (95% CI) P value Quinine group (n=86) Artemether-lumefantrine group (n=89)
Treatment failure (%)* 35.3 (25.6 to 47.4)† 4.1 (1.3 to 12.0)† 31.3 (19.4 to 31.1) <0.001
Treatment failure (%)‡ 23.1 (14.9 to 35.0)§ 0§ 23.1 (13.2 to 33.1) <0.001
*Any early treatment failure, late clinical failure, or late parasitological failure.
†Unadjusted by genotyping.
‡Any early treatment failure, late clinical failure, or late parasitological failure caused by recrudescence.
§Adjusted by genotyping.
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has a shorter treatment course than quinine and has
excellent tolerability. However, it must be adminis-
tered twice a day, ideally with a fatty meal, two factors
that have led to concern about its effectiveness. Our
results and those of other recent studies reassure us
that, even with suboptimal adherence (19% of partici-
pants had <100% adherence), artemether-lumefan-
trine will likely perform well as a routine first line
antimalarial therapy in Africa. However, other studies
have shown levels of adherence to artemisinin based
combinationtherapies lower than those in our study,
35
or observed that the efficacy of unsupervised artemisi-
ninbasedcombinationtherapieswaslowerthanthatof
supervised therapy,
3637 emphasising the need for
increased attention to education of patients and care
givers on the appropriate dosing of new antimalarial
therapies.
Conclusions
Wefoundthattheeffectivenessofasevendaycourseof
quinine for the treatment of uncomplicated malaria in
Ugandan children was significantly lower than that of
the new artemisinin based combination therapy arte-
mether-lumefantrine. These results question the advi-
sability of the recommendation for quinine as therapy
for uncomplicated malaria in Africa. Rather, it seems
that another artemisinin based combination therapy
will be more appropriate to treat uncomplicated
malariaevenafterinitialtreatmentfailurewithanarte-
misinin based combination therapy. This strategy
seems reasonable in Africa, as nearly all clinical fail-
ures after use of highly effective artemisinin based
combination therapies (artemether-lumefantrine, arte-
sunate-amodiaquine, and dihydroartemisinin with
piperaquine) are new infections, not recrudescence.
However, the use of artemisinin based combination
therapies as both first line and second line therapy for
uncomplicated malaria has not yet been tested in a
therapeutictrial,andsuchevaluationshouldbeaprior-
ity. Furthermore, the increasing use of quinine as first
line therapy for uncomplicated malaria should be dis-
couraged. It is hoped that increasing access to new
drugs will allow most Africans with uncomplicated
malaria to be treated promptly with artemisinin based
combination therapies, the most effective available
therapies for this condition.
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